AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
NCT06320717
·
clinicaltrials.gov ↗
RECRUITING
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
OTHER:
Blood sample
Sponsor
Roswell Park Cancer Institute